Skip to main content
Log in

A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder

  • ORIGINAL ARTICLE
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

 This study evaluated the efficacy and tolerability of new extended-release (ER) tolterodine for the treatment of overactive bladder in women. In this subpopulation analysis of a double-blind multicenter trial, 1235 female patients were randomized to oral therapy with tolterodine ER 4 mg once daily (n=417), tolterodine IR 2 mg twice daily (n=408) or placebo (n=410) for 12 weeks. Both formulations reduced the mean number of urge incontinence episodes per week (both P=0.001 vs placebo); tolterodine ER was more effective than tolterodine IR (P=0.036). Both formulations significantly improved all other micturition chart variables compared to placebo. Dry mouth was the most common adverse event. There were no safety concerns. Toltrodine ER 4 mg once daily is effective and well tolerated in the treatment of women with overactive bladder, and reduces urge incontinence episodes more than the existing IR twice-daily formulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Consortia

Additional information

Received: 15 May 2002 / Accepted: 21 July 2002

Acknowledgement This study was sponsored by a grant from Pharmacia Corporation.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swift, S., Garely, A., Dimpfl, T. et al. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int Urogynecol J 14, 50–55 (2003). https://doi.org/10.1007/s00192-002-1009-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-002-1009-0

Navigation